MedTrace Logo

Evaluation of the Immune Response to SARS-CoV-2 Among Patients With Covid-19 in Costa Rica

NCT04537338 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2020-09-03

No results posted yet for this study

Summary

Describe the immune response of patients affected by SARS-CoV-2, including an assessment of the types of antibodies elicited by the infection, specifc antibody titers for the different isotypes, evolution of the antibody response over time, protective efficacy and immune correlates of protection.

investigate genetic determinants of Covid-19 and of the imune response to this condition.

Finally, the study will investigate secondary infection rate and its determinants among household contacts of Covid-19 patients.

Conditions

Interventions

GENETIC

1. Characterize the immune response after infection with SARS-CoV-2

1\. Characterize the immune response after infection with SARS-CoV-2 in terms of type of antibodies (IgM, IgG, IgA), seroconversion, maximum antibody levels, , and response to different viral proteins/antigens

Sponsors & Collaborators

  • Caja Costarricense de Seguro Social

    collaborator OTHER_GOV

  • Fundación INCIENSA (FUNIN)

    collaborator UNKNOWN

  • Ministerio de Salud de Costa Rica

    collaborator UNKNOWN

  • Institutos Nacionales de Salud, USA Instituto Alemán del Cáncer

    collaborator UNKNOWN

  • Agencia Costarricense de Investigaciones Biomedicas (ACIB)

    collaborator UNKNOWN

  • Agencia Costarricense de Investigaciones Biomedicas

    lead OTHER

Principal Investigators

  • Rolando Herrerro, Médico · Agencia Costarricense de Investigaciones Biomedicas

Eligibility

Min Age
6 Months
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-14
Primary Completion
2022-09-14
Completion
2022-09-14

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04537338 on ClinicalTrials.gov